---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-22-000065"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:10:41.007109+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Allogene expects FDA clearance for first allogeneic CAR T pivotal trial; Q2 net loss $74.8M

## Summary
- FDA clearance expected in coming weeks for Phase 2 pivotal trial of ALLO-501A in LBCL; would be first allogeneic CAR T pivotal trial.
- Ended Q2 2022 with $686M cash, cash equivalents and investments; net loss $74.8M ($0.52 per share).
- Full year GAAP OpEx guided to low end of $360M-$390M; cash burn ~$250M for 2022.
- CF1 manufacturing facility operational; projected capacity ~20,000 doses/year; earned LEED Gold designation.

## SEC filing metadata
- accession: 0001737287-22-000065
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000065/0001737287-22-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000065/allo-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-22-000065
- JSON: https://secwatch.observer/filing/0001737287-22-000065.json
- Plain text: https://secwatch.observer/filing/0001737287-22-000065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.